naltrexone has been researched along with Bowel Diseases, Inflammatory in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lie, MRKL; Paulides, E; van der Woude, CJ | 1 |
| Kienzl, M; Schicho, R; Storr, M | 1 |
| de Lima, A; Fuhler, GM; Lie, MRKL; Peppelenbosch, MP; van der Ent, C; van der Giessen, J; van der Woude, CJ | 1 |
| Corsetti, M; Pannemans, J | 1 |
| Fitzpatrick, L; Harms, JF; Matters, GL; McGovern, C; Nilo, N; Parikh, A; Smith, JP | 1 |
| Blum, HE; Kreisel, W; Opitz, OG; Thimme, R | 1 |
3 review(s) available for naltrexone and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases.
Topics: Analgesics, Opioid; Cannabinoids; Endocannabinoids; Enteric Nervous System; Gastrointestinal Microbiome; Humans; Inflammatory Bowel Diseases; Marijuana Use; Medical Marijuana; Naltrexone; Narcotic Antagonists; Opioid Peptides; Receptors, Cannabinoid; Receptors, Opioid, mu; Self Medication | 2020 |
Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?
Topics: Analgesics, Opioid; Animals; Antidiarrheals; Constipation; Defecation; Diarrhea; Gastrointestinal Motility; Gastrointestinal Tract; Humans; Imidazoles; Inflammatory Bowel Diseases; Laxatives; Morphinans; Naltrexone; Narcotic Antagonists; Phenylalanine; Polyethylene Glycols; Quaternary Ammonium Compounds; Receptors, Opioid, mu; Signal Transduction | 2018 |
[Cholestatic liver diseases].
Topics: Anti-Bacterial Agents; Antibodies, Antineutrophil Cytoplasmic; Anticholesteremic Agents; Antipruritics; Autoimmune Diseases; Bile Ducts; Cholagogues and Choleretics; Cholangiography; Cholangitis; Cholangitis, Sclerosing; Cholestasis; Cholestyramine Resin; Clinical Enzyme Tests; Diagnosis, Differential; Hepatitis, Autoimmune; Humans; Immunosuppression Therapy; Inflammatory Bowel Diseases; Liver Cirrhosis; Liver Cirrhosis, Biliary; Liver Transplantation; Naloxone; Naltrexone; Narcotic Antagonists; Ondansetron; Plasmapheresis; Ursodeoxycholic Acid | 2004 |
2 trial(s) available for naltrexone and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study.
Topics: Crohn Disease; Humans; Inflammation; Inflammatory Bowel Diseases; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Remission Induction | 2022 |
Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.
Topics: Adult; Cell Line, Tumor; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoscopy; Epithelial Cells; Female; Humans; Inflammation; Inflammatory Bowel Diseases; Interleukin-8; Intestinal Mucosa; Male; Middle Aged; Naltrexone; Remission Induction; Wound Healing | 2018 |
1 other study(ies) available for naltrexone and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
The opioid antagonist naltrexone improves murine inflammatory bowel disease.
Topics: Animals; Biomarkers; Dextran Sulfate; Disease Models, Animal; Gene Expression Regulation; Humans; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukin-12; Interleukin-6; Male; Mice; Naltrexone; Narcotic Antagonists; Weight Loss | 2008 |